Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 4
F·Filter
Reset allT2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
4 sources
- 2022RCTmoderaten=88
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial
Hua X, Church K, Walker W, +5 · Journal of Alzheimer's Disease
First-in-human Phase I trial of fosgonimeton (ATH-1017), the prodrug of the active metabolite ATH-1001 that descends from the Wright/Harding dihexa program — 88 subjects across young healthy, elderly healthy, and Alzheimer's cohorts, with the drug safe and well-tolerated and signals of qEEG gamma-power induction and P300 latency normalization in the AD cohort.
- 2004RCTmoderate
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Diamond LE, Earle DC, Rosen RC, +2 · International Journal of Impotence Research
First-in-human safety and efficacy study of intranasal PT-141 in healthy men and men with erectile dysfunction — established the central-mechanism erectile response, dose-related flushing and nausea profile, and the pharmacokinetic floor on which Palatin's male-indication development program was built before it was abandoned for the eventual female HSDD approval.
- 1996RCTmoderaten=36
Synthetic ACTH analogue Semax displays nootropic-like activity in humans
Kaplan AY, Kochetova AG, Nezavibatko VN, +2 · Neuroscience Research Communications
The first international report of Semax cognitive effects in humans, from the Ashmarin inventor group at Moscow State University — three sub-studies (operator performance, EEG during cognitive load, EEG under post-hyperventilation cerebral ischaemia) establishing a long-lasting (20-24 hr post single intranasal dose) cognitive signal at 0.25-1.0 mg.
- 1987RCTmoderaten=14
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
Schneider-Helmert D · European Neurology
Across 14 middle-aged chronic insomniacs given DSIP for seven consecutive nights under double-blind placebo control, night-sleep efficiency rose to control-population values and the effect persisted through the first placebo washout night — the cleanest single-investigator EEG-monitored evidence for DSIP in disturbed human sleep.